Dimenoxadol

Dimenoxadol
Clinical data
Other names	Dimenoxadol, Estocin
ATC code	none;
Legal status
Legal status	AU: S9 (Prohibited substance); BR: Class A1 (Narcotic drugs); CA: Schedule I; DE: Anlage I (Authorized scientific use only); US: Schedule I; UN: Psychotropic Schedule I;
Identifiers
	IUPAC name 2-(dimethylamino)ethyl 2-ethoxy-2,2-diphenylacetate;
CAS Number	509-78-4 ;
PubChem CID	17036;
DrugBank	DB01461 ;
ChemSpider	16137 ;
UNII	4D65PBX0VK;
KEGG	D12672 ;
ChEMBL	ChEMBL2104309;
CompTox Dashboard (EPA)	DTXSID5057759 ;
Chemical and physical data
Formula	C20H25NO3
Molar mass	327.424 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(C)C;
	InChI InChI=1S/C20H25NO3/c1-4-24-20(17-11-7-5-8-12-17,18-13-9-6-10-14-18)19(22)23-16-15-21(2)3/h5-14H,4,15-16H2,1-3H3 ; Key:RHUWRJWFHUKVED-UHFFFAOYSA-N ;
	(verify)

Dimenoxadol (INN; also known as dimenoxadole (BAN) or dimenoxadole; brand name Estocin in Russia) is an opioid analgesic which is a benzilic acid derivative, closely related to benactyzine (an anticholinergic). Further, the structure is similar to methadone and related compounds like dextropropoxyphene.

It was invented in Germany in the 1950s, and produces similar effects to other opioids, including analgesia, sedation, dizziness and nausea.

In the United States it is a Schedule I Narcotic controlled substance with an ACSCN of 9617 and a 2013 annual aggregate manufacturing quota of zero.